Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone

• Published in: Human reproduction (Oxford) 2015-01, Vol.30 (1), p.170-178
• Main Authors: Hamdine, O., Eijkemans, M.J.C., Lentjes, E.W.G., Torrance, H.L., Macklon, N.S., Fauser, B.C.J.M., Broekmans, F.J.
• Format: Article
• Language: English
• Subjects: Anti-Mullerian Hormone - blood; Gonadotropin-Releasing Hormone - antagonists & inhibitors; Humans; Multivariate Analysis; Ovulation Induction; Retrospective Studies; Treatment Outcome
• ISSN: 0268-1161; 1460-2350
• DOI: 10.1093/humrep/deu266

STUDY QUESTION What is the clinical value of anti-Müllerian hormone (AMH) for the prediction of high or low ovarian response in controlled ovarian stimulation for IVF using GnRH antagonist treatment? SUMMARY ANSWER AMH as a single test has substantial accuracy for ovarian response prediction in GnRH antagonist treatment for IVF, with a higher accuracy for predicting a high response than for low response. WHAT IS KNOWN ALREADY The role of AMH and other patient characteristics in ovarian response prediction has been studied extensively in long GnRH agonist protocols; however, little information is available regarding the clinical value in GnRH antagonists. STUDY DESIGN, SIZE, DURATION This is an observational (retrospective) substudy as part of an ongoing cohort study. A total of 487 patients scheduled for IVF/ICSI between 2006 and 2011 were included in the study. PARTICIPANTS/MATERIALS, SETTING, METHODS Patients with a regular cycle who underwent their first IVF/ICSI cycle with GnRH antagonist treatment while receiving a starting dose of 150 or 225 IU recombinant FSH were included in the study. Patients were divided into three subgroups according to the following ovarian response categories: high (>15 oocytes or cycle cancellation), normal (4–15 oocytes) and low (